Hyperleptinemia – Non-Haemodynamic Risk Factor for the Left Ventricular Hypertrophy Development in Hypertensive Overweight Females

Obesity is directly and strongly associated with hypertension and left ventricular hypertrophy (LVH). Development of LVH is multifactorial, caused both by haemodynamic and non-haemodynamic factors. Hypertension is the main haemodynamic factor. Humoral mechanisms, as a non-haemodynamic factor for LVH development, have not been completely explained. The aim of this study is to determine whether hyperleptinemia can be one of humoral – non-haemodynamic factor inducing LVH together with haemodynamic factors in overweight females. The study was done on thirty six adult, overweight female patients, body mass index in range 25–30 kg/m2. Patients are nondiabetic with regular renal function. Twenty one female patients were hypertensive with left ventricular hypertrophy. Control group included fifteen hypertensive female patients without left ventricular hypertrophy. In all patients was determined glucose profile and creatinine clearance, cholesterol, triglycerides, LDL, HDL.Weight, high, circumference of the waist and hips was taken. Cardiovascular determination was done applying two-dimensional ultrasound. Serum leptin level was measured using radioimmunoassay method (RIA). Results showed that serum leptin level was significantly higher in hypertensive, overweight females with LVH. This suggests that non-haemodynamic factors, such as hyperleptinemia, participate in left ventricular hypertrophy development together with haemodynamic factors in adult hypertonic, overweight females

Analysis of patients with thyroid cancer treated at the Department of nuclear medicine, radiation protection and pathophysology over the period 1968 - 1998

Cilj studije je bio izvršiti analizu oboljelih od karcinoma štitnjače u razdoblju od 1968. do 1998. godine, koji su liječeni u Centru za bolesti štitnjače Odjela za nuklearnu medicinu, zaštitu od zračenja i patofiziologiju KB Osijek. Liječenje ukupno 281 bolesnik od karcinoma štitne žlijezde. Najmlađi bolesnik imao je 7 godina, a najstariji 82 godine u momentu postavljanja dijagnoze. Srednja dob je bila 45 godina. Najviše je bilo papilamih (N=156), folikulamih (N=56), medulamih (N=28), a zatim slijede Hurthle (N=16), anaplastični (N=5) i ostali (N=5). Češće obolijevaju žene (N=226) nego muškarci (N=55), a pojava bolesti je najveća u 4, 5. i 6. desetljeću života. Tumor se javlja najčešće kao solitami čvor (N=106), te difuzna ili nodozna struma (N=132), a u 31 oboljelog kao povećani limfni čvor na vratu. Analizirana je važnost scintigrafije u postavljanju sumnje na karcinom štitnjače. Također su uspoređeni nalazi citološke punkcije sa definitivnom histološkom dijagnozom. Uspoređen je opseg operacijskoga liječenja te liječenja radiojodom. Prikazanje i mortalitet od karcinoma štitnjače kroz tridesetogodišnje razdoblje.The purpose of the study was to analyse patients treated for thyroid cancer at the Centre for thyroid diseases, Department of Nuclear Medicine, Radiation Protection and Pathophysiology, Osijek Clinical Hospital over the period 1968-1998. The total of 281 patients with thyroid cancer were treated. The youngest patient was 7 and the oldest one 82 years old at the time the diagnosis was verified. The mean age was 45. They were diagnosed as follows: papillary cancer (N=156), follicular (N=56), medullar (N=28), Hurthle (N=16), anaplastical (N=5) and other (N=5). The disease occurred more often in females (N= 226) than in males (N=55). The frequency of the disease is the highest in the 4th, 5th and 6th decades of life. The tumours mostly presented as a solitary node (N=106) and as diffuse or nodular goiter (N=132). In 31 patients, the disease appeared as an enlarged lymph node on the neck. The value of the scintigraphy in suspected thyroid cancer was analysed. Also, the results of cytological punction and final pathohistological diagnoses were compared. The extent of surgical treatment and treatment with radioiodine was compared. Mortality rate of thyroid cancer in the 30-year period was present

Analysis of patients with thyroid cancer treated at the Department of nuclear medicine, radiation protection and pathophysology over the period 1968 - 1998

Cilj studije je bio izvršiti analizu oboljelih od karcinoma štitnjače u razdoblju od 1968. do 1998. godine, koji su liječeni u Centru za bolesti štitnjače Odjela za nuklearnu medicinu, zaštitu od zračenja i patofiziologiju KB Osijek. Liječenje ukupno 281 bolesnik od karcinoma štitne žlijezde. Najmlađi bolesnik imao je 7 godina, a najstariji 82 godine u momentu postavljanja dijagnoze. Srednja dob je bila 45 godina. Najviše je bilo papilamih (N=156), folikulamih (N=56), medulamih (N=28), a zatim slijede Hurthle (N=16), anaplastični (N=5) i ostali (N=5). Češće obolijevaju žene (N=226) nego muškarci (N=55), a pojava bolesti je najveća u 4, 5. i 6. desetljeću života. Tumor se javlja najčešće kao solitami čvor (N=106), te difuzna ili nodozna struma (N=132), a u 31 oboljelog kao povećani limfni čvor na vratu. Analizirana je važnost scintigrafije u postavljanju sumnje na karcinom štitnjače. Također su uspoređeni nalazi citološke punkcije sa definitivnom histološkom dijagnozom. Uspoređen je opseg operacijskoga liječenja te liječenja radiojodom. Prikazanje i mortalitet od karcinoma štitnjače kroz tridesetogodišnje razdoblje.The purpose of the study was to analyse patients treated for thyroid cancer at the Centre for thyroid diseases, Department of Nuclear Medicine, Radiation Protection and Pathophysiology, Osijek Clinical Hospital over the period 1968-1998. The total of 281 patients with thyroid cancer were treated. The youngest patient was 7 and the oldest one 82 years old at the time the diagnosis was verified. The mean age was 45. They were diagnosed as follows: papillary cancer (N=156), follicular (N=56), medullar (N=28), Hurthle (N=16), anaplastical (N=5) and other (N=5). The disease occurred more often in females (N= 226) than in males (N=55). The frequency of the disease is the highest in the 4th, 5th and 6th decades of life. The tumours mostly presented as a solitary node (N=106) and as diffuse or nodular goiter (N=132). In 31 patients, the disease appeared as an enlarged lymph node on the neck. The value of the scintigraphy in suspected thyroid cancer was analysed. Also, the results of cytological punction and final pathohistological diagnoses were compared. The extent of surgical treatment and treatment with radioiodine was compared. Mortality rate of thyroid cancer in the 30-year period was present

Low Adiponectin Serum Level – Reduced Protective Effect on the Left Ventricular Wall Thickness

Adiponectin, secreted by fat tissue, is down – regulated in obesity and may be involved in obesity-related disorders. It has anti-inflammatory, antiatherosclerotic and antidiabetic effect. Obesity is a strong predictor for hypertension and cardiovascular diseases. Recent studies showed that adiponectin level has important role in metabolic disorders, arterial hypertension and ischemic heart disease but its effect on left ventricular hypertrophy (LVH) has not been fully clarified. The aim of this research is to determine whether the protective effect of adiponectin against development of left ventricular hypertrophy is decreased in hypertensive overweight patients. The study included 61 adult, overweight hypertensive patients, with body mass index in range 25–30 kg/m2. Patients had regular morning glucose serum values and regular creatinine level. They were divided into four groups, according to sex and the presence of LVH. There were 16 female and 15 male hypertensive patients with LVH and 15 female and 15 male hypertensive patients without LVH, who were a control group. Glucose profile, lipidogram, creatinine clearance and anthropometric measures were determined in all patients. Cardiovascular measurements were taken applying two-dimensional ultrasound. Adiponectin serum level was measured using enzyme immunoassay (ELISA). Results showed that adiponectin serum level was significantly lower in hypertensive, overweight females and males with LVH than in the control groups without LVH. Adiponectin serum level did not correlate significant with intraventricular or with posterior wall thickness of left ventricle. Hypoadiponectinemia presents part of neurohumoral, non-haemodynamic system who contributes to obesity-related hypertension and left ventricular hypertrophy development. Low adiponectin level together with others adipokines, cytokines and chemokines secreted by fat tissue could contribute to pathophysiologic changes of the myocardium via unknown molecular mechanisms yet

Low Adiponectin Serum Level – Reduced Protective Effect on the Left Ventricular Wall Thickness

Adiponectin, secreted by fat tissue, is down – regulated in obesity and may be involved in obesity-related disorders. It has anti-inflammatory, antiatherosclerotic and antidiabetic effect. Obesity is a strong predictor for hypertension and cardiovascular diseases. Recent studies showed that adiponectin level has important role in metabolic disorders, arterial hypertension and ischemic heart disease but its effect on left ventricular hypertrophy (LVH) has not been fully clarified. The aim of this research is to determine whether the protective effect of adiponectin against development of left ventricular hypertrophy is decreased in hypertensive overweight patients. The study included 61 adult, overweight hypertensive patients, with body mass index in range 25–30 kg/m2. Patients had regular morning glucose serum values and regular creatinine level. They were divided into four groups, according to sex and the presence of LVH. There were 16 female and 15 male hypertensive patients with LVH and 15 female and 15 male hypertensive patients without LVH, who were a control group. Glucose profile, lipidogram, creatinine clearance and anthropometric measures were determined in all patients. Cardiovascular measurements were taken applying two-dimensional ultrasound. Adiponectin serum level was measured using enzyme immunoassay (ELISA). Results showed that adiponectin serum level was significantly lower in hypertensive, overweight females and males with LVH than in the control groups without LVH. Adiponectin serum level did not correlate significant with intraventricular or with posterior wall thickness of left ventricle. Hypoadiponectinemia presents part of neurohumoral, non-haemodynamic system who contributes to obesity-related hypertension and left ventricular hypertrophy development. Low adiponectin level together with others adipokines, cytokines and chemokines secreted by fat tissue could contribute to pathophysiologic changes of the myocardium via unknown molecular mechanisms yet

Circadian Rhythm of Blood Leptin Level in Obese and Non-Obese People

Leptin, an adipose tissue hormone, has circadian variations in its secretion. Aims of this study were to show how circadian rhythm depends on fat tissue distribution in obese and non-obese subjects. The research was carried out on 70 subjects (37 men and 33 women) with an average body mass index (BMI) of 25.22 kg/m2. Concentration of leptin in blood was measured at 8.30 a.m., 12.30 p.m. and 6.30 p.m. Basal leptin level correlated strongly with all isolated regions of subcutaneous fat tissue in women and obese subjects. Circadian changes of blood leptin level in non-obese people are more significant than these changes in obese people. Differences in circadian pattern of leptin secretion between obese and non-obese subjects were probably caused by enlarged volume of subcutaneous fat tissue in obese people. Lean subjects have subcutaneous fat in physiological range which allows influence of some hormones (insulin or cortizol) or food intake on leptin secretion